Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $650
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on Chemed (NYSE:CHE) and raises the price target from $625 to $650.
February 29, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Michael Wiederhorn maintains an Outperform rating on Chemed and raises the price target from $625 to $650.
The increase in price target by a reputable analyst suggests a positive outlook on Chemed's stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100